|
WO2020260683A1
|
|
Systemic autoimmune diseases diagnostic and prognostic method
|
|
WO2020152280A1
|
|
Lsd1 inhibitors for use in the treatment of type 2 diabetes
|
|
WO2020099572A1
|
|
Polynucleotide for safer and more effective immunotherapies
|
|
WO2020035598A1
|
|
Is2 element to improved integration-defective lentiviral vectors
|
|
WO2019193202A1
|
|
Hemostatic efficacy of a nanostructured fibrin agarose hydrogel
|
|
WO2019053224A1
|
|
Mesenchymal stem cells for use in a method of treatment of radiation-induced brain injury
|
|
WO2019030422A1
|
|
Use of levothyroxine for the treatment of diabetes mellitus
|
|
WO2018172588A1
|
|
Use of mok modulating agents for the treatment of inflammatory diseases and neurodegenerative diseases
|
|
WO2018154165A1
|
|
Nanoparticles modified with alkoxy-silane derivatives
|
|
WO2018083274A1
|
|
Lent-on-plus system for conditional expression in human stem cells
|
|
AU2017315174A1
|
|
Cell suspension for use in the treatment of lower extremity peripheral artery disease
|
|
ES2696902A1
|
|
NANOPARTICLES BASED ON SILICA MODIFIED ON A SURFACE TO IMPROVE CHEMICAL ADSORPTION (Machine-translation by Google Translate, not legally binding)
|
|
ES2690861A1
|
|
MEANS OF CULTIVATION WITH LIEADOS PLAQUETARIOS (Machine-translation by Google Translate, not legally binding)
|
|
WO2017032612A1
|
|
Stem cells with enhanced clonogenic, migratory and homing capacities
|
|
CA3015577A1
|
|
Agents for increasing the secretion of anti-inflammatory cytokines
|
|
EP3075845A1
|
|
Novel mesenchymal stem cell surface marker
|
